Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of vibegron in men with overactive bladder symptoms receiving pharmacologic therapy for benign prostatic hyperplasia
2018-003136-72Phase 3Completed
- Sponsor
- Urovant Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vibegron in overactive bladder (OAB), sponsored by Urovant Sciences. Started Sep 2021; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2018-003136-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003136-72.